Malignant gliomas represent about 70 % of all brain tumors [18] . Despite advances in standard therapy consisting of surgery,
radiation therapy and chemotherapy, gliomas remain an essentially fatal disease, with a median survival time of 10 to 12 months and a 2-year survival rate of 8 % to 12 %. Without debulking surgery, survival time can be less than 6 months with a 2-year survival rate of 0 % [3, 6, 8, 14, 18] Reasons for the lack of therapeutic success may be migrating tumor cells that spread into the surrounding healthy tissues, creating the basis for inevitable recurrences, and further disseminations as well as the insufficient chemoperfusion into the brain due to the brain-blood-barrier [1, 7] . Genetic alterations in glioblastoma multiforme, the most frequent histological type of glioma, are likely to affect cell proliferation and cell cycle control, as well as invasive metastatic growth [19] . Furthermore, disruption of cell death pathways also contributes to the pathogenesis of glioblastoma multiforme and may result in resistance to chemotherapy and radiation [22] . Therefore, innovative therapeutic strategies have been based on drugs targeting cellular proliferation [7] , invasion and angiogenesis [4] . Local therapy may have a temporary effect, but to be curative, treatment must reach all the tumor cells and target various therapeutic approaches [12] .
The limited therapeutic options for patients who fail to respond to standard therapy have resulted in the development of various adjuvant therapies that aim at the control of tumor growth while reducing the severity of side effects associated especially with systemic treatments.
Hyperthermia combined with radiation therapy and/or chemotherapy has been reported as a potential cancer treatment, although the underlying molecular mechanisms of this procedure are not well understood. A number of studies have shown that hyperthermia inhibits angiogenesis, enhances chemo-and radio-sensitivity and induces a high concentration of drugs in a tumor [11, 27] .
The effect of hyperthermia on intracranial malignancies has been evaluated in a number of experimental and clinical studies using various technical approaches, e.g. microwave and laser devices [2, 5, 9, 10, 13, 16, 17, 20, 21, 23, 25, 29] .
While many investigators point to potential benefits for patients who receive adjuvant hyperthermia, it should also be noted that the application of heat to the brain Electro-hyperthermia is an advanced hyperthermia technique that has been applied either alone or in combination with radiation-and/or chemotherapy [10, 21] .
Electro-hyperthermia is considered to be selective through the higher conductivity other conventional episodic, bolus and/or high dose chemotherapy [15] . An in-vitro study showed that hyperthermia potentiates the effect of temozoline in tumor cells [19] .
The purpose of this retrospective study was to evaluate the feasibility of electro-hyperthermia in patients with malignant glioma and its effect on survival times.
Description of the trial
This study was a retrospective evaluation of patients with malignant brain glioma, who were treated with electro-hyperthermia during a period of 56 months. All patients had inoperable, sub-totally resected or recurrent brain glioma and a Karnofsky
Performance Score of > ¼ 40 %. Table 1 .
As shown in Figure 1 , the age-distribution was near to normal (p < 0.001, Chisquare test for discrete variables). There As expected, the overall survival time was highest in patients with diffuse astrocytoma and lowest in the glioblastoma multiforme group. Categorized survival times are shown in Table 3 .
Results and discussion
Results of the subgroup analysis by age (< 50 years, > 50 years) are summarized in Table 4 and Table 5 and graphically displayed in Figure 6 .
The analysis by age group greater and below 50 years of age shows a significantly higher median survival time for patients younger than 50 years in both time from first diagnosis (p < 0.0003) and time from first electro-hyperthermia (p < 0.009).
As shown in Figure 7 , the relative dependency to dose-threshold (DT) was not significant for the overall median survival time (p ¼ 0.129) and statistically significant for survival time from the first electro-hyperthermia treatment (p < 0.01).
No serious side effects related to electro-hyperthermia were reported (see Table 6 ). Patients tolerated the treatments well during the whole treatment period.
During the treatment, most of the patients were relaxed, some even fell asleep. In subsequent MRI follow up examinations, no edema formation was observed (Figure 8 ).
Discussion
The overall median survival time for patients with mostly advanced malignant glioma who received adjuvant electro-hy- 
